Pancreatitis News and Research

RSS
Pancreatitis is inflammation of the pancreas. The pancreas is a large gland behind the stomach and close to the duodenum—the first part of the small intestine. The pancreas secretes digestive juices, or enzymes, into the duodenum through a tube called the pancreatic duct. Pancreatic enzymes join with bile—a liquid produced in the liver and stored in the gallbladder—to digest food. The pancreas also releases the hormones insulin and glucagon into the bloodstream. These hormones help the body regulate the glucose it takes from food for energy.

Normally, digestive enzymes secreted by the pancreas do not become active until they reach the small intestine. But when the pancreas is inflamed, the enzymes inside it attack and damage the tissues that produce them.

Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. In severe cases, bleeding, infection, and permanent tissue damage may occur.
FDA approves first non-insulin drug for treatment of pediatric patients with type 2 diabetes

FDA approves first non-insulin drug for treatment of pediatric patients with type 2 diabetes

Fibrinogen a key player in health and disease, says new study

Fibrinogen a key player in health and disease, says new study

Blocking protein-digesting enzyme may help improve metabolic health

Blocking protein-digesting enzyme may help improve metabolic health

Deletion of ATDC gene prevents development of pancreatic cancer in mice

Deletion of ATDC gene prevents development of pancreatic cancer in mice

New enzyme biomarker test indicates diseases and bacterial contamination

New enzyme biomarker test indicates diseases and bacterial contamination

New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

Researchers discover how protein pair regulates cellular calcium signals

Researchers discover how protein pair regulates cellular calcium signals

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Researchers identify sex-specific genetic risk factor for pancreatic cancer

Researchers identify sex-specific genetic risk factor for pancreatic cancer

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

New minimally invasive therapy shows promise for long-term reversal of Type 1 diabetes

New minimally invasive therapy shows promise for long-term reversal of Type 1 diabetes

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications

Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications